-
XellSmart Bio-Pharmaceutical Achieves Milestone with First Patient Enrollment in Global iPSC Clinical Study for ALS
•
XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd., in collaboration with Shanghai East Hospital (Tongji University Affiliated East Hospital) and Liu Zhongmin’s team, has successfully enrolled the first patient in the global clinical study for “Clinical Grade iPSC-Derived Subtype Neural Progenitor Cell Therapy for Amyotrophic Lateral Sclerosis (ALS).” This marks a significant milestone…
-
Stem-Cell Startup Xellsmart Secures Over RMB 100 Million in Series B1 Financing for Neurological Therapies
•
Xellsmart, a stem-cell startup headquartered in Suzhou, has reportedly secured over RMB 100 million (USD 14.08 million) in a Series B1 financing round. The round was led by Tialong/Taikun Equity Investment Fund, with additional investments from Septwolves Venture Capital and Sky World Capital, alongside returning investors Frees Fund, Qiming Venture…
-
Stem-Cell Startup Xellsmart Earns FDA Orphan Drug Designation for ALS Therapy
•
Xellsmart, a stem-cell startup headquartered in Suzhou, has announced that it has received orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for its induced pluripotent stem cell (iPSC) derived subtype neural precursor cell therapy, targeting amyotrophic lateral sclerosis (ALS). ALS is a devastating motor neuron disease…
-
Xellsmart Raises RMB 200M in Series A1 Round for Stem-Cell Therapies
•
Xellsmart, a stem-cell startup based in Suzhou, has reportedly raised over RMB 200 million (USD 27.6 million) in a Series A1 financing round. The round was co-led by Qiming Venture Partners, Lilly Asia Ventures, Xiamen Jinyuan Zhanhong Investment, and China-Singapore Suzhou Industrial Park Development Group. Other investors included Oriza Holdings,…
